# Optimising Molecular Radionuclide Therapy

> **NCT04922801** · — · COMPLETED · sponsor: **King's College London** · enrollment: 50 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Hyperthyroidism
- Thyroid Cancer
- Thyroid Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** Nuclear Medicine whole-body
- **DIAGNOSTIC_TEST:** SPECT/CT imaging.
- **DIAGNOSTIC_TEST:** PET/CT imaging.
- **DEVICE:** Patient-led radiation monitor (SELFIE)
- **DIAGNOSTIC_TEST:** LAB TEST

## Key facts

- **NCT ID:** NCT04922801
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-09
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-11-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922801, "Optimising Molecular Radionuclide Therapy". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04922801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*